Industry Developments
United States
BMI View: Despite the revenue decrease in Q411 due to the expiration of Zyprexa (olanzapine)'s patent protection, Eli Lilly's attractiveness to investors is increasing, albeit from...
2012-02-02United States
BMI View: Investor perception of Pfizer during 2012 will be dominated by four key factors: the successful divestment of its non-core nutritional and animal health assets, whether the...
2012-02-02United States
BMI View: Abbott Laboratories has an enlightened appreciation of the two major current trends in the global pharmaceutical market. The US-based company is performing well in emerging...
2012-02-01Chile
BMI View: Multinational healthcare companies are seeking expansion in Chile through acquisitions of local distributors to avoid high production costs, which are due to the strict regulation...
2012-01-31United States
BMI View: We think 2011 was a very good year for Bristol-Myers Squibb (BMS). It outperformed all other companies in terms of share price performance, it has a very strong product pipeline...
2012-01-30Argentina
BMI View: Argentina's retail pharmacy sector should provide a very rewarding market for multinational companies. However, government policy and legislation is heavily biased towards...
2012-01-27Colombia
BMI View: Colombia's growing economy and stable political environment provide incentives for multinational companies to expand their businesses to meet the increasing regional demand...
2012-01-26Mexico
BMI View: We now hold a more favourable opinion on Mexico's pharmaceutical market. Improved macroeconomics and tougher regulation on medical claims in advertisements will benefit local...
2012-01-25
